Biotech News News 11 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

New York, January 14, 2026, 14:54 EST — During regular session Shares of Praxis Precision Medicines jumped roughly 8% on Wednesday, bucking the weaker trend in the broader market. By mid-afternoon, the Nasdaq-listed biotech was trading at $303.23, up $22.40.

14 January 2026

Biotech News·FDA Updates·Pharma Industry·Stock Market

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

New York, Jan 14, 2026, 13:09 EST — Regular session Cogent Biosciences shares rose about 8% on Wednesday, lifting the biotech’s stock toward recent highs as investors focused on a near-term U.S. regulatory checkpoint for its lead drug candidate, bezuclastinib.

14 January 2026

Biotech News·FDA Updates·Financial Analysis·Investment Strategies·Stock Market

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

New York, January 14, 2026, 13:09 EST — Regular session underway. Shares of Viking Therapeutics climbed roughly 11% on Wednesday, rising from a $30.44–$34.08 range to $34.06 by 1:09 p.m. EST. The move came amid renewed deal speculation in obesity

14 January 2026

Biotech News·Investment Trends·Pharma Industry·Stock Market

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

New York, Jan 14, 2026, 12:55 (EST) — Regular session Shares of Edgewise Therapeutics Inc (EWTX.O) were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and

14 January 2026

Biotech News·Clinical Trials·Investment Analysis·Pharmaceutical Industry·Stock Market

Beyond Air (XAIR) stock whipsaws after NeuroNOS deal — premarket drop follows 150% rally

NEW YORK, January 14, 2026, 05:10 (EST) — Premarket Shares of Beyond Air, Inc. plunged 16.4% to $1.83 in premarket action Wednesday, following a wild 150% surge that closed Tuesday at $2.19. The stock swung between $1.37 and $2.66 during

14 January 2026

Biotech News·Financial Analysis·Investing·Stock Market

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

NEW YORK, Jan 13, 2026, 16:19 EST — After-hours Shares of Harmony Biosciences Holdings Inc (HRMY) slid 6.4% on Tuesday to close at $35.82, after trading as low as $34.69. The move comes as investors work through a pipeline reshuffle

13 January 2026

Biotech News·Financial Updates·Investment Analysis·Pharma Industry·Stock Market

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

New York, Jan 13, 2026, 13:22 (EST) — Regular session Arcus Biosciences shares rose nearly 5% on Tuesday after Goldman Sachs upgraded the biotech to “Buy” and lifted its price target. The stock was up 4.8% at $22.32 in early

13 January 2026

Biotech News·Financial Analysis·Healthcare·Investments·Stock Market

Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally

New York, Jan 13, 2026, 05:28 ET — Premarket Beam Therapeutics Inc (BEAM.O) slipped roughly 0.6% to $33.47 in premarket trading Tuesday, following a sharp 22.3% jump during Monday’s session. The shares climbed as high as $36.44 Monday and saw

13 January 2026

Biotech News·FDA Updates·Investment Insights·Market Trends·Stock Market

ImmunityBio stock today: IBRX slips in premarket as U.S.-Saudi biotech summit nears

New York, Jan 13, 2026, 05:42 (ET) — Premarket ImmunityBio shares were down 0.8% in premarket trading on Tuesday at $2.57, as of 5:00 a.m. ET. Around 13,000 shares had traded by that point, according to Public.com data. Premarket trading

13 January 2026

Biotech News·Financial Updates·Stock Market

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

New York, Jan 12, 2026, 20:02 EST — Market closed Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations. The decline hit as investors

13 January 2026

Biotech News·Earnings Reports·Investment Analysis·Pharmaceuticals·Stock Market

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

New York, Jan 12, 2026, 09:54 EST — Regular session Atara Biotherapeutics shares plunged about 56% to $6.03 in early trading after the U.S. Food and Drug Administration rejected its cell therapy tabelecleucel, marketed as EBVALLO in Europe, for a

12 January 2026

Biotech News·FDA Updates·Investment Strategies·Pharmaceutical Industry·Stock Market

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

ZURICH, Jan 11, 2026, 17:40 CET — The market has closed. Roche Holding shares rose 0.4% on Friday following news that China’s MediLink Therapeutics inked a licensing deal with the Swiss pharma giant for an experimental cancer drug. The stock

11 January 2026

Biotech News·Cancer Research·Investment·Pharmaceuticals·Stock Market

Biotech News News 11 January 2026 - 14 January 2026